Revvity Inc
XMUN:PKN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Revvity Inc
XMUN:PKN
|
US |
|
S
|
Siemens AG
SWB:SIE
|
DE |
|
L
|
Las Vegas Sands Corp
F:LCR
|
US |
|
L
|
Leonardo SpA
XMUN:FMNB
|
IT |
|
C
|
Centrus Energy Corp
AMEX:LEU
|
US |
|
Coca-Cola Femsa SAB de CV
NYSE:KOF
|
MX |
|
W
|
Walmart Inc
XBER:WMT
|
US |
|
MS&AD Insurance Group Holdings Inc
F:59M
|
JP |
|
Aena SME SA
F:A44
|
ES |
|
PhosAgro PAO
LSE:PHOR
|
RU |
|
A
|
Abbvie Inc
SWB:4AB
|
US |
|
Wynn Resorts Ltd
NASDAQ:WYNN
|
US |
|
Nine Dragons Paper (Holdings) Ltd
OTC:NDGPF
|
HK |
|
R
|
Randstad NV
XMUN:RSH
|
NL |
|
Gogo Inc
NASDAQ:GOGO
|
US |
|
Blackstone Inc
NYSE:BX
|
US |
|
China Construction Bank Corp
SSE:601939
|
CN |
|
I
|
Iberdrola SA
DUS:IBE1
|
ES |
|
Edwards Lifesciences Corp
NYSE:EW
|
US |
|
B
|
BIO-Key International Inc
XBER:BJO
|
US |
Revvity Inc
Revvity makes tools and tests used in laboratories that study biology and diagnose disease. Its products include laboratory instruments, reagents, assay kits, software, and related services that help customers measure biological signals, run genetic and biochemical tests, and analyze results. The company serves drug developers, biotech and academic research labs, and clinical and public health laboratories. The company makes money in a few main ways: it sells instruments and software systems upfront, and it also sells the consumable chemicals, test kits, and service contracts that customers keep buying after the equipment is installed. That gives Revvity a mix of one-time sales and recurring revenue tied to the ongoing use of its platforms. In diagnostics, its products help labs detect and monitor disease; in research, they help scientists discover and develop new medicines. What makes Revvity’s business model distinct is that it sits in the middle of the lab workflow. It does not just sell standalone equipment; it sells the tools, tests, and support that labs use repeatedly to generate data and make decisions. That makes the company an important supplier to both healthcare testing and life sciences research, where customers care about accuracy, reliability, and easy-to-run workflows.
Revvity makes tools and tests used in laboratories that study biology and diagnose disease. Its products include laboratory instruments, reagents, assay kits, software, and related services that help customers measure biological signals, run genetic and biochemical tests, and analyze results. The company serves drug developers, biotech and academic research labs, and clinical and public health laboratories.
The company makes money in a few main ways: it sells instruments and software systems upfront, and it also sells the consumable chemicals, test kits, and service contracts that customers keep buying after the equipment is installed. That gives Revvity a mix of one-time sales and recurring revenue tied to the ongoing use of its platforms. In diagnostics, its products help labs detect and monitor disease; in research, they help scientists discover and develop new medicines.
What makes Revvity’s business model distinct is that it sits in the middle of the lab workflow. It does not just sell standalone equipment; it sells the tools, tests, and support that labs use repeatedly to generate data and make decisions. That makes the company an important supplier to both healthcare testing and life sciences research, where customers care about accuracy, reliability, and easy-to-run workflows.
Beat and raise: Revvity said second-quarter results came in above the high end of expectations, and it raised full-year organic growth, margin, and EPS guidance.
Diagnostics strength: Diagnostics delivered another very strong quarter, with 11% organic growth, helped by reproductive health, newborn screening, and immunodiagnostics outside China.
Life Sciences improving: Life Sciences was softer in the quarter because of Signals software timing and comps, but management said order momentum improved materially and backlog is the strongest in 3 to 4 years.
AI demand emerging: Management described growing demand tied to AI-driven drug discovery, including orders from non-traditional customers building lab workflows that need biological data, validation, and screening.
Capital return and leverage: Revvity generated strong cash flow, paid off a EUR 500 million note, and said leverage should move below 3x gross by year-end and toward 2x net.
China exit advancing: The company signed a definitive agreement to divest its China immunodiagnostics business and still expects the deal to close by the end of 2027.
